TITLE

Perioperative Management of Warfarin Therapy: To Bridge or Not to Bridge, That Is the Question

AUTHOR(S)
Douketis, James D.
PUB. DATE
June 2008
SOURCE
Mayo Clinic Proceedings;Jun2008, Vol. 83 Issue 6, p628
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article presents the author's perspective on a study concerning the perioperative practice of administering bridging anticoagulation with subcutaneous low-molecular-weight heparin (LMWH). He remarks that the novel aspect of the study is the inclusion of a comparison group of patients who did not receive bridging therapy. He contends that the comparison rate of thromboembolism in the bridging versus no-bridging groups is troublesome because the two groups differed significantly.
ACCESSION #
32617209

 

Related Articles

  • Efficient use of bridge anticoagulation therapy. Perez, Mirza E.; Graham, Mark G.; Sivaraman, Priya // Patient Care;Oct2006, Vol. 40 Issue 10, p38 

    The article discusses the efficiency of using anticoagulation therapy for the treatment and prevention of thromboembolism. Warfarin has anticoagulation affects. There are several options for the periprocedural management of anticoagulation. Suggested protocols are presented for bridge therapy...

  • Cancer and thrombosis: implications of published guidelines for clinical practice. Khorana, A. A. // Annals of Oncology;Oct2009, Vol. 20 Issue 10, p1619 

    Cancer is a frequent finding in patients with thrombosis, and thrombosis is much more prevalent in patients with cancer, with important clinical consequences. Thrombosis is the second most common cause of death in cancer patients. Venous thromboembolism (VTE) in cancer is also associated with a...

  • Traditional anticoagulant therapy: Why abandon half a century of success? Bussey, Henry // American Journal of Health-System Pharmacy;10/15/2002, Vol. 59 Issue 20, pS3 

    The benefits of low-molecular-weight heparins (LMWHs) over heparin and warfarin in treating and preventing thromboembolic disorders are discussed, Numerous advantages are associated with using heparin for treating and preventing thromboembolic disorders. Heparin's short half-life allows for...

  • New Anticoagulants: Focus on Venous Thromboembolism. G�mez-Outes, Antonio; Lecumberri, Ram�n; Pozo, Carmen; Rocha, Eduardo // Current Vascular Pharmacology;Jul2009, Vol. 7 Issue 3, p309 

    Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) and/or arterial thromboembolism. The therapeutic arsenal of anticoagulants available to clinicians is mainly composed by unfractionated heparin (UFH),...

  • Secondary Prophylaxis with Warfarin for Venous Thromboembolism. Büller, Harry R.; Prins, Martin H. // New England Journal of Medicine;8/14/2003, Vol. 349 Issue 7, p702 

    Editorial. Offers an editorial on the two phases in the treatment of patients with symptomatic venous thromboembolism. Therapy that consists of either subcutanous low-molecular-weight heparin or intravenous unfractionated heparin; Phase involving oral vitamin K antagonists such as warfarin;...

  • Treatment of Venous Thromboembolism and Long-Term Prevention of Recurrence: Present Treatment Options and Ximelagatran. Eriksson, Henry // Drugs;2004 Supplement 1, Vol. 64, p37 

    Despite the effectiveness of anticoagulant therapy for the treatment of acute venous thromboembolism and the prevention of recurrent venous thromboembolism, existing antithrombotic therapies are suboptimal. Unfractionated heparin, low-molecular-weight heparin (LMWH) and warfarin have practical...

  • Current Options in the Prevention of Thromboembolic Disease. Ansell, Jack; Bergqvist, David // Drugs;2004 Supplement 1, Vol. 64, p1 

    Significant advances in the pharmacological prophylaxis of venous thromboembolism have occurred since warfarin and unfractionated heparin were introduced for this indication nearly 60 years ago. Despite these advances, coumarin derivatives such as warfarin remain the only orally active...

  • Anticoagulation for venous thromboembolism. Eikelboom, John W.; Ginsberg, Jeffrey S.; Hirsh, Jack // BMJ: British Medical Journal (International Edition);3/31/2007, Vol. 334 Issue 7295, p645 

    The article presents an editorial about the use of anticoagulant therapy to treat venous thromboembolism. A randomized controlled trial in the current issue by Campbell and colleagues examined the optimal duration of oral anticoagulant therapy. The drugs warfarin and heparin were investigated in...

  • Safe practice for patients receiving anticoagulant therapy. Lankshear, Annette; Harden, Jane; Simms, Jonathan // Nursing Standard;1/20/2010, Vol. 24 Issue 20, p47 

    Venous thrombolembolism, although largely preventable, continues to be a major cause of death in hospitalised patients. The anticoagulant drugs used to prevent and treat this condition require careful and knowlegeable management. Nurses working in acute and community settings have an important...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics